Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
331 GBX | +3.28% | +1.22% | +50.45% |
May. 09 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
May. 09 | Molten Ventures wins UK MoD supply contract | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+50.45% | 408M | B | ||
+11.91% | 114B | B+ | ||
+11.60% | 105B | B+ | ||
-4.68% | 23.83B | B+ | ||
-0.82% | 21.73B | B | ||
-10.12% | 18.1B | A- | ||
-42.12% | 16.34B | A- | ||
-17.47% | 16.13B | B | ||
+2.77% | 13.75B | C+ | ||
+34.58% | 11.76B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- OXB Stock
- Ratings Oxford Biomedica plc